Boston Scientific (NYSE: BSX) Invests $1.5B in MiRus Heart Valve Startup
Boston Scientific commits $1.5 billion investment in MiRus, a transcatheter heart valve maker, expanding its interventional cardiology portfolio.
Boston Scientific Corporation (NYSE: BSX) is a company in the Health Care sector, listed on the NYSE. This page collects all Alpha Stocks Insight coverage of BSX: earnings reports, analyst actions, and company news, updated as new articles are published. 4 articles since April 24, 2026.
Boston Scientific's coronary lithotripsy catheter met primary safety and effectiveness endpoints in pivotal FRACTURE IDE trial, clearing a key regulatory hurdle.
Boston Scientific commits $1.5 billion investment in MiRus, a transcatheter heart valve maker, expanding its interventional cardiology portfolio.
BSX drops 5.51% post-earnings; valuation compression suggests margin pressure concerns despite Q1 beat.
BSX gains modestly after slashing guidance, as Wall Street recalibrates expectations and identifies valuation opportunity.
Important Legal Disclaimer
This is for informational purposes only and is not financial, investment, or tax advice. Past performance is no guarantee of future results. We are not licensed advisors. For Swiss residents: This does not constitute a public offer under FINSA. For EU residents: Not MiFID II compliant advice. For US residents: Not SEC-registered advice. Always consult a qualified professional. Investing involves risk of loss.
Affiliate disclosure: This site may contain affiliate links to brokerage platforms. If you open an account through one of our links, we may earn a commission at no additional cost to you. Affiliate relationships do not influence our editorial content or stock coverage decisions.
Important Legal Disclaimer: This is for informational purposes only and is not financial, investment, or tax advice. Past performance is no guarantee of future results. We are not licensed advisors. For Swiss residents: This does not constitute a public offer under FINSA. For EU residents: Not MiFID II compliant advice. For US residents: Not SEC-registered advice. Always consult a qualified professional. Investing involves risk of loss.